Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Processa Pharmaceuticals ( (PCSA) ) has shared an update.
On February 12, 2026, Processa Pharmaceuticals, Inc. reported that its Binding Term Sheet dated June 17, 2025 with Intact Therapeutics regarding the drug candidate PCS12852 had expired without the parties executing a definitive license agreement. The related proposed amendment to Processa’s existing License Agreement with Yuhan Corporation was also not entered into, leaving none of the parties with further obligations under the expired Term Sheet and potentially limiting Processa’s previously anticipated development or commercialization plans for PCS12852.
The lapse of the Term Sheet with Intact Therapeutics ended a prospective licensing pathway for PCS12852 that had been under discussion since mid-2025, signaling a shift in Processa’s strategic options for that asset. This development may affect how the company positions PCS12852 within its pipeline and could alter expectations among partners and investors regarding future collaborations or deal structures tied to this program.
The most recent analyst rating on (PCSA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.
Spark’s Take on PCSA Stock
According to Spark, TipRanks’ AI Analyst, PCSA is a Neutral.
The score is held down primarily by weak financial performance (no revenue, recurring losses, and ongoing cash burn) and bearish technicals (trading well below major moving averages with negative MACD). Valuation contributes little support due to the negative P/E and lack of dividend yield.
To see Spark’s full report on PCSA stock, click here.
More about Processa Pharmaceuticals
Processa Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on developing drug candidates, including licensed assets such as PCS12852, through collaborations with partners and licensors in the pharmaceutical industry.
Average Trading Volume: 813,396
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.94M
Learn more about PCSA stock on TipRanks’ Stock Analysis page.